A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age (Q35045424)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age |
scientific article |
Statements
1 reference
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age (English)
1 reference
Sodiomon B Sirima
1 reference
Jerald Sadoff
1 reference
Edith C Bougouma
1 reference
Amidou Diarra
1 reference
Alfred B Tiono
1 reference
Alphonse Ouédraogo
1 reference
Issiaka Soulama
1 reference
Amadou T Konate
1 reference
Jean Baptiste Yaro
1 reference
Souleymane Sanon
1 reference
Youssouf Kaboré
1 reference
Adama Gansane
1 reference
Désiré Kargougou
1 reference
Esperance Ouédraogo
1 reference
David Kangoye
1 reference
Noelie Henri
1 reference
Nora L Watson
1 reference
Valerie Brown
1 reference
Jenny Hendriks
1 reference
Maria Grazia Pau
1 reference
Isabella Versteege
1 reference
Edison Wiesken
1 reference
Issa Nebie
1 reference
11 November 2013
1 reference
11 November 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference